China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 rose 27.37% year-over-year to ¥7.18 billion, with year-to-date revenue up 11.38% to ¥21.99 billion.

• Net profit attributable to shareholders fell 4.26% year-over-year for the quarter and dropped 20.51% year-to-date.

• Major changes in financials and balance sheet driven by the acquisition of Tian Shi Li.

Financial highlights

• Q3 net profit attributable to shareholders: ¥537.6 million, down 4.26% year-over-year.

• Year-to-date net profit: ¥2.35 billion, down 20.51% year-over-year.

• Operating cash flow for the period: ¥2.93 billion, down 8.70% year-over-year.

• Basic and diluted EPS for Q3: ¥0.32, down 5.88% year-over-year; year-to-date EPS: ¥1.42, down 20.22%.

• Total assets at period end: ¥56.56 billion, up 41.12% from year-end 2024.

Outlook and guidance

• Significant increases in R&D and fixed assets signal ongoing investment and expansion.